Active, not recruitingPHASE1, PHASE2NCT05383079

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peter MacCallum Cancer Centre, Australia
Principal Investigator
Prof Michael Hofman
Peter MacCallum Cancer Centre, Australia
Intervention
Lutetium-177 PSMA-I&T(drug)
Enrollment
36 enrolled
Eligibility
18 years · MALE
Timeline
2022 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05383079 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials